Our story

A new startup — with an established track record.
CureLab Veterinary is a subsidiary of CureLab Oncology, Inc. The parent company, focused solely on human immune-oncology, was established in 2012 by seasoned scientists and business experts, with Nobel Laureates and immediate past members of the US president’s cabinet on its advisory board.
After the clinical benefits of the company’s main product became evident for pets as well, CureLab Veterinary was created in November 2020 to be focused exclusively on bringing CureLab’s products to save lives and improve the welfare of cats, dogs, and horses.


About us


Founder and CEO

Over 25 years of biotech and entrepreneurial experience. Currently Senior Research Fellow of molecular biology at University of Ariel, Israel; editorial board member for journals Aging and Cell Cycle, advisor at We Fund Health. The past achievements and activities include but are not limited to drug development from concept to market authorization, patents in all major jurisdictions, advisory role for successful exits, consulting for Fortune 100 companies, establishing and leading international R&D consortia, senior authorship in papers and books.
About us

Robert Devlin, D.V.M., M.B.A.

Executive Consultant

About us


VP of R&D

Over 30 years of successful discovery and development experience and problem-solving skills in R&D of anti-cancer drugs from bench to bedside. Over 80 papers, over 4,000 references. Past academic appointments with Boston University and Boston Biomedical Research Institute.
About us


Director of Basic Research

Over 30 years of biomedical research, over 20 years of tenured faculty professorship at University of Camerino, Italy, where was Head of the Translational Biology Laboratory, 20 years of service as editor-in-chief, editorial board member and a reviewer for vaccination and immunobiology journals.